Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

Journal of Gastroenterology

Volumn 45, Issue 6, 2010, Pages 656-665

  Nakagawa, Mina ^a   Sakamoto, Naoya ^a   Ueyama, Mayumi ^a   Mogushi, Kaoru ^a   Nagaie, Satoshi ^a   Itsui, Yasuhiro ^b   Azuma, Seishin ^a   Kakinuma, Sei ^a   Tanaka, Hiroshi ^a   Enomoto, Nobuyuki ^c   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Soka Municipal Hospital   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chronic hepatitis C; Combination therapy; Hepatitis C virus (HCV); Interferon sensitivity determining region (ISDR); PEG IFN plus RBV therapy

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; AGED; AMINO ACID SUBSTITUTION; ANOREXIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENDER; GENE MUTATION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PSYCHOPATHY; RETINOPATHY; RETROSPECTIVE STUDY; SKIN DISEASE; THROMBOCYTE COUNT;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; MUTATION; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955716832     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0195-7     Document Type: Article

References (48)

1. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology. 1997;25:1527-38.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science. 1989;244: 359-62.
3. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991;337:1058-61.
4. Dibisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot-study of ribavirin therapy for chronic hepatitis-C. Hepatology. 1992;16:649-54.
5. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591-8.
6. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351:83-7.
7. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-32.
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.
9. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-67.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marionos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
11. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995;96:224-30.
12. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77-81.
13. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 1997;25:750-3.
14. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol. 1994;75:1361-9.
15. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular-cloning of the human hepatitis-C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 1990;87:9524-8.
16. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and nonvirological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372-80.
17. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007;46:1357-64.
18. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon Alfa. Hepatology. 1997;25:740-4.
19. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon- alfa therapy in French patients. J Hepatol. 1997;27:72-7.
20. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology. 1997;113:567-72. (Pubitemid 27351784)
21. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol. 1997;53:118-26.
22. Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, et al. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol. 1999;30:1023-7.
23. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol. 1999;58:353-8.
24. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 1999;30:1004-13.
25. Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, et al. Efficacy of ribavirin plus interferon-alpha in patients aged C60 years with chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:989-95.
26. Hung CH, Chen CH, Lee CM, Wu CM, Hu TH, Wang JH, et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepatitis. 2008;15:58-65.
27. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferonribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. J Med Virol. 2006;78:83-90.
28. Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha- 2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009;81:640-9.
29. Yen YH, Hun CH, Hu TH, Chen CH, Wu CM, Vvang JH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;27:72-9.
30. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepatitis. 2003;10: 87-94.
31. Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, et al. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferonribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. J Med Virol. 2007;79:35-40.
32. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008;48:1753-60.
33. Murphy MD, Rosen HR, Marousek GI, Chou SW. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci. 2002;47:1195-205.
34. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 2003;23:426-33.
35. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 1997;25:745-9.
36. Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Hamano K, et al. Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology. 2003;311:376-83.
37. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230:217-27.
38. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998;18:5208-18.
39. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen XY, Taguwa S, et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88- dependent signaling pathway in macrophage cell lines. J Virol. 2007;81:8953-66.
40. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9:1089-97.
41. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis. 2001;183:1195-203.
42. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol. 2001;63:8-16.
43. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972-4.
44. Maekawa S, Enomoto N, Sakamoto N, Kurosaki M, Ueda E, Kohashi T, et al. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HCJ4 isolate to replicate efficiently in Huh-7 cells. J Viral Hepatitis. 2004;11:394-403.
45. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, et al. Site-specific mutation of the interferon sensitivity- determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepatitis. 2006;13:582-90.
46. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97.
47. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C types 1 and 4 patients with slow virologic response. Gastroenterology 2009 [Epub ahead of print].
48. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Prolonged treatment with pegylated interferon a 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2009 [Epub ahead of print].